INOVIO PHARMACEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted orterminated any contracts, instructions or written plans for the purchase or sale of our securities.
On August 5, 2024, we provided notice to BofA Securities, Inc., RBC Capital Markets, LLC and Oppenheimer & Co. Inc. to terminate the 2021 Sales Agreement described in Part I, Item 2 of this report. We sold an aggregate of 4,289,403 shares of our common stock pursuant to the 2021 Sales Agreement for net proceeds of $93.6 million.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.